牛津-阿斯利康COVID-19疫苗后微小病变肾病伴严重急性肾损伤一例
本文报告一例71岁男性在接种首剂ChAdOx1 nCoV-19(AZD1222)疫苗后13天出现微小病变肾病(MCD)伴严重急性肾损伤(AKI)。患者表现为肾病综合征、AKI及严重高血压,因难治性高钾血症和高容量血症伴少尿启动血液透析,肾活检示MCD和急性肾小管损伤,经糖皮质激素治疗后肾功能和蛋白尿改善。
要点
- 接种牛津-阿斯利康COVID-19疫苗后13天可出现新发MCD伴严重AKI。
- 表现为肾病综合征、AKI和严重高血压,需警惕并考虑肾活检。
- 经验性糖皮质激素治疗后肾功能和蛋白尿改善,血液透析可停用。
核心结论
- 本病例报告描述了接种牛津-阿斯利康COVID-19疫苗后新发微小病变肾病(MCD),补充了辉瑞-BioNTech疫苗后MCD的少数已发表病例报告。
- MCD是否与COVID-19疫苗接种真正相关尚需进一步报告和研究阐明。
研究设计与样本
- 单例病例报告:71岁男性,有血脂异常病史,基线血清肌酐0.7mg/dL,接种首剂ChAdOx1 nCoV-19(AZD1222)疫苗。
主要发现
- 接种疫苗后13天出现肾病综合征、AKI和严重高血压。
- 血清白蛋白2.6g/dL,尿蛋白-肌酐比2,321mg/mmol。
- 因难治性高钾血症和高容量血症伴少尿启动血液透析。
- 肾活检示微小病变肾病(MCD)和急性肾小管损伤。
- 经验性糖皮质激素治疗(3次甲泼尼龙冲击后高剂量泼尼松)后肾功能和蛋白尿改善,治疗开始后38天停用血液透析。
关键数值与推荐
- 血清白蛋白2.6g/dL,尿蛋白-肌酐比2,321mg/mmol。
- 肾活检示MCD和急性肾小管损伤。
- 经验性糖皮质激素方案:3次甲泼尼龙冲击后高剂量泼尼松。
- 血液透析在治疗开始后38天停用。
临床怎么用
- 接种牛津-阿斯利康COVID-19疫苗后出现肾病综合征和AKI时应考虑MCD可能并及时行肾活检。
- 对疑似快速进展性肾小球肾炎者可经验性使用糖皮质激素,严重AKI伴难治性高钾血症和高容量血症时及时启动血液透析。
局限性
- 单例病例报告,无法确立MCD与COVID-19疫苗接种的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report a case of minimal change disease (MCD) with severe acute kidney injury (AKI) following the first injection of the ChAdOx1 nCoV-19 (AZD1222) vaccine from Oxford-AstraZeneca against coronavirus disease 2019 (COVID-19). A 71-year-old man with a history of dyslipidemia and a baseline serum creatinine of 0.7mg/dL presented with nephrotic syndrome, AKI, and severe hypertension 13 days after receiving the Oxford-AstraZeneca vaccine. Refractory hyperkalemia and hypervolemia with oligoanuria prompted initiation of hemodialysis. His serum albumin was 2.6g/dL and his urinary protein-creatinine ratio was 2,321mg/mmol. Given a high suspicion for rapidly progressive glomerulonephritis, empirical glucocorticoid treatment was initiated (3 methylprednisolone pulses followed by high-dose prednisone). A kidney biopsy showed MCD and acute tubular injury. Kidney function and proteinuria subsequently improved, and hemodialysis was discontinued 38 days after the start of therapy. This case describes de novo MCD after the Oxford-AstraZeneca vaccine. It adds to the few published case reports of MCD after the Pfizer-BioNTech COVID-19 vaccine. Further reports and studies will be needed to elucidate whether MCD is truly associated with COVID-19 vaccination.
引用
- Leclerc S, Royal V, Lamarche C, et al. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report. Am J Kidney Dis. 2021. PMID: 34242687. doi:10.1053/j.ajkd.2021.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。